Velocity Clinical Research expands to UK

London, U.K., 17 November 2022: Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, today announces its expansion into the U.K. with the acquisition of multi-site company Egin Research.

Velocity is the first US-based clinical research sites business to expand into Europe, bringing its total number of dedicated research locations to 42. The addition of Egin Research’s two sites increases Velocity’s European site footprint to three, after its first European purchase in Hamburg, Germany in July 2022 and further growth expected over the next 12 months.

Dominic Clavell, Executive Vice President, Europe, said, “The size and importance of the UK market for clinical research cannot be underestimated. There is a focus on clinical trial regulation reform in a post-Brexit era to bring new treatments to patients faster. 

“The region significantly contributed to COVID vaccine research, leading to the UK Government's recent £800 million cash injection into the clinical trials industry to boost innovation, growth and patient safety. Velocity’s global scale and timely expansion into the UK means we are primed to take full advantage of the growing dedicated clinical research ecosystem and demand.”

Egin Research is a multi-site research company co-founded by Shivagami Muthiah and Dr. Ahmed Elshashai in 2019. Both co-founders have considerable experience setting up and running dedicated research facilities, having previously worked at a leading site management organisation (SMO). 

Shivagami Muthiah, Business Director of Egin Research, believes that Egin’s ethos mirrors that of Velocity Clinical Research. “We are a team of doctors, nurses, pharmacists and healthcare assistants with a passion for research. With Velocity’s support we will be able to accelerate our plan to expand the network, making clinical trials ever more available to patients.”

Egin has plans for continued growth on the back of their early successes, as it integrates into Velocity’s global network. With support from Velocity, Egin will expand its therapeutic areas to recruit patients into trials for all ambulatory chronic diseases and some acute diseases.  

Dr. Ahmed Elshashai, Chief Investigator at Egin Research, added, “We strive to provide the best experience for participants by considering their involvement in clinical trials as a journey that we go through together. It was evident from the start that Velocity had the same values in patient welfare and research quality.”

Velocity’s sites are wholly owned and fully integrated via a centralised infrastructure and common technology backbone, allowing for superior patient enrolment and consistent, high-quality data delivery. As a result, Clinical Research Organisations and big pharmaceutical companies can benefit from simplified access to international clinical research.